UK reg­u­la­tor warns of se­vere eye re­ac­tions fol­low­ing use of Sanofi and Re­gen­eron's Dupix­ent

The UK’s Med­i­cines and Health­care Reg­u­la­to­ry Agency (MHRA) on Tues­day warned of some new and se­ri­ous eye-re­lat­ed side ef­fects fol­low­ing the use of Sanofi and Re­gen­eron’s atopic der­mati­tis and asth­ma treat­ment Dupix­ent (dupilum­ab).

While Dupix­ent is al­ready as­so­ci­at­ed with cas­es of con­junc­tivi­tis and al­ler­gic con­junc­tivi­tis, dry eye and with in­fre­quent cas­es of ker­ati­tis and ul­cer­a­tive ker­ati­tis, the MHRA is call­ing on health pro­fes­sion­als to be on the look­out for any of these eye-re­lat­ed side ef­fects as “it is not cur­rent­ly pos­si­ble to pre­dict who may ex­pe­ri­ence the rar­er and most se­vere oc­u­lar ad­verse re­ac­tions, such as ul­cer­a­tive ker­ati­tis.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER